Autonomix Medical, Inc. — Form 8-K
Filed August 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On August 24, 2026, Autonomix Medical agreed with an investor to exercise 857,462 warrants (Series D-1 and D-2, issued July 15, 2026) at $5.75/share, generating ~$4.9M gross proceeds. In exchange, the company issued two new unregistered warrant series (E-1 and E-2): 535,913 shares each, exercisable at $6.25/share, 5-year term. New warrants represent 62.5% of exercised shares. Company committed to file resale registration statement within 15 days, maintain trading market listing, and restrict equity issuances through Jan 11, 2027 (no variable-rate transactions). Closing expected ~August 26, 2026. Maxim Group LLC acted as financial advisor.
Why this rating
~$4.9M cash inflow is 78% of $6.3M market cap—material liquidity event. New warrants at 9% premium ($6.25 vs $5.75) and lock-up restrictions show confidence but dilution risk substantial relative to tiny company size.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.